CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BPRPS1PRPS1 MUTATIONPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaLi et al., 2015
DPRPS1T303SPredictiveSupportsResistanceB-lymphoblastic Leukemia/lymphomaMercaptopurine,ThioguanineLi et al., 2015
DPRPS1L191FPredictiveSupportsResistanceB-lymphoblastic Leukemia/lymphomaThioguanine,MercaptopurineLi et al., 2015
DPRPS1D183EPredictiveSupportsResistanceB-lymphoblastic Leukemia/lymphomaThioguanine,MercaptopurineLi et al., 2015
DPRPS1K176NPredictiveSupportsResistanceB-lymphoblastic Leukemia/lymphomaThioguanine,MercaptopurineLi et al., 2015
DPRPS1N144SPredictiveSupportsResistanceB-lymphoblastic Leukemia/lymphomaMercaptopurine,ThioguanineLi et al., 2015
DPRPS1S103IPredictiveSupportsResistanceB-lymphoblastic Leukemia/lymphomaMercaptopurine,ThioguanineLi et al., 2015
DPRPS1S103NPredictiveSupportsResistanceB-lymphoblastic Leukemia/lymphomaMercaptopurine,ThioguanineLi et al., 2015
DPRPS1A87TPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaMercaptopurine,ThioguanineLi et al., 2015
DPRPS1M115TPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaMercaptopurine,ThioguanineLi et al., 2015
Av::ROS1FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibWu et al., 2018
CBCR::ABL1Fusion AND ABL1 E450QPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
BCTNNB1Exon 3 MutationDiagnosticSupportsPositiveChildhood MedulloblastomaClifford et al., 2006
BFUS::DDIT3FusionDiagnosticSupportsPositiveLiposarcomaKubo et al., 2010
BLPP::HMGA2Fusion OR HMGA2::LPP FusionDiagnosticSupportsNegativeLiposarcomaKubo et al., 2010
BCDKN2ALossPrognosticSupportsPoor OutcomeAcute Lymphoblastic LeukemiaZhang et al., 2019
CPIK3CAV955IPredictiveSupportsResistanceColorectal CancerCetuximabXu et al., 2017
CABL1Double PhPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
CBCR::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeBoer et al., 2017
CETV6::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
CSSBP2::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
DFLT3D835YPredictiveSupportsSensitivity/ResponseCancerGilteritinibMori et al., 2017
AFGFR2::vFusion OR FGFR2::? FusionPredictiveSupportsSensitivity/ResponseCholangiolocellular CarcinomaPemigatinibAbou-Alfa et al., 2020
BPML::RARAFusion AND PML A216VPredictiveSupportsResistanceAcute Promyelocytic LeukemiaArsenic TrioxideLiu et al., 2016
BMYOD1L122RDiagnosticSupportsPositiveSpindle Cell RhabdomyosarcomaRekhi et al., 2016
CKIF5B::RETFusion AND ( RET G810C OR RET G810S OR RET G810R )PredictiveSupportsResistanceLung Non-small Cell CarcinomaSelpercatinibSolomon et al., 2020
CIGH::CRLF2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
DPTENLossPredictiveSupportsResistanceHer2-receptor Positive Breast CancerLapatinibEichhorn et al., 2008
AETV6::NTRK3FusionDiagnosticSupportsPositiveCongenital FibrosarcomaKnezevich et al., 1998
DFLT3Y842CPredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibWilliams et al., 2013
DFLT3Y842CPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaLestaurtinibWilliams et al., 2013
APALB2MutationPredictiveSupportsSensitivity/ResponseCastration-resistant Prostate CarcinomaOlaparibde Bono et al., 2020
AATMMutationPredictiveSupportsSensitivity/ResponseCastration-resistant Prostate CarcinomaOlaparibde Bono et al., 2020
BMN1::BEND2FusionDiagnosticSupportsPositiveAstroblastoma, MN1-alteredSturm et al., 2016
BZFTA::RELAFusionPrognosticSupportsPoor OutcomeSupratentorial Ependymoma, ZFTA Fusion–positivePajtler et al., 2015
CVHLR167W (c.499C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseSizdahkhani et al., 2017
AMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCapmatinibWolf et al., 2020
Bv::RETFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelpercatinibDrilon et al., 2020
ARETMutationPredictiveSupportsSensitivity/ResponseMedullary Thyroid CarcinomaSelpercatinibWirth et al., 2020
Av::RETFusionPredictiveSupportsSensitivity/ResponseThyroid CancerSelpercatinibWirth et al., 2020
DFGFR3S249COncogenicSupportsOncogenicityBladder Urothelial CarcinomaBernard-Pierrot et al., 2006
BSMARCB1LossDiagnosticSupportsPositiveAtypical Teratoid Rhabdoid TumorJudkins et al., 2004
CLMNA::NTRK1FusionPredictiveSupportsSensitivity/ResponseColorectal CancerEntrectinibSartore-Bianchi et al., 2016
CETV6::NTRK3FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaMethotrexate,Larotrectinib,EtoposideSchewe et al., 2019
DFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibMori et al., 2017
DETV6::NTRK3FusionOncogenicSupportsOncogenicityB-lymphoblastic Leukemia/lymphomaRoberts et al., 2018
BBCOR::CCNB3FusionDiagnosticSupportsPositiveSarcoma With BCOR Genetic AlterationsPeters et al., 2015
BCIC::DUX4FusionDiagnosticSupportsPositiveCIC-rearranged SarcomaAntonescu et al., 2017
BBRAFV600EPredictiveSupportsSensitivity/ResponsePapillary Thyroid CarcinomaVemurafenibBrose et al., 2016
CANO10::RAF1FusionPredictiveSupportsSensitivity/ResponseMelanomaTrametinibKim et al., 2018
Page 20 of 96
PreviousNext